Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MK-1084 + SKB264 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MK-1084 | MK 1084|MK1084|Calderasib | KRAS G12C inhibitor 36 | MK-1084 is a selective inhibitor of KRAS G12C, which inhibits downstream signaling, potentially resulting in decreased tumor cell proliferation, and antitumor activity (NCI Drug Dictionary, Ann Oncol 34 (2023): S466-S467). | |
| SKB264 | SKB 264|SKB-264|ADC SKB264|MK-2870|MK 2870|MK2870|Sacituzumab tirumotecan | TROP2 Antibody 18 | SKB264 is an antibody-drug conjugate (ADC) composed of a monoclonal antibody that targets trophoblast cell surface protein 2 (TROP2) linked to a topoisomerase I inhibitor, which delivers the drug to TROP2-expressing tumor cells, potentially resulting in antitumor activity (Cancer Res (2024) 84 (7_Supplement): CT038). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07286149 | Phase Ib/II | Cetuximab + MK-1084 MK-1084 + SKB264 MK-1084 + Patritumab deruxtecan | A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) | Recruiting | USA | ISR | 0 |